Cadila Healthcare, a Ahmedabad headquartered pharmaceutical company owned by Zydus Group, said it has partnered with Switzerland-based global biopharmaceutical company Neovii to launch an drug to reduce the strength of the body’s immune system in India.
The drug named Grafalon is extensively used in solid organ transplants and stem cell transplant, said the company.
The market for transplant-immuno therapies is estimated at Rs 483 crore, the company added.
Zydus will market this therapy through Zydus Trans-immune a division that offers a range of therapies related to transplant medicine.
With the inclusion of Grafalon (R) Zydus Trans-immune becomes a leading player in transplant-immunotherapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant.
Organ transplantation is the most preferred option for patients with end-stage organ failure since both survival and quality of life are superior as compared to patients who live without transplantation, the company further added.
One of the major challenges in organ transplantation is graft rejection.
In most cases transplant rejection occurs when transplanted tissue is rejected by the recipient’s immune system which destroys the transplanted tissue.
Likewise, stem cell transplantation remains key treatment option for those suffering from haematological conditions including malignancies.
Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon (R).
Grafalon(R) enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of transplant recipients around the world.
More than 200,000 patients till date, in over 50 countries, have been treated With Grafalon (R) currently an estimated 10000 Solid organ transplant & stem cell transplants are taking place annually across 200 plus transplant centres in India.